Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
This article compares yields from SP 500 funds and multi-asset retirement portfolios, detailing factors that influence income streams.
25,151 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Publicly traded lenders, brokerages, and builders posted a mixed bag of Q1 2026 results as higher borrowing costs and...
Doximity is due to report Q4 results after the close, with analysts keyed to FY2027 guidance and margin trajectory as...
Gene Smith, the former Ohio State athletic director, has been elected to M/I Homes’ board of directors. The move come...
Doximity sits at a crossroads: a robust physician network with multiple monetization channels, yet facing disruption ...
Rocket Lab stands as the only public space stock with a direct line to actual launches and defense demand, even as Sp...
A single-session drop in the 3X leveraged FNGU ETN trimmed a $10,000 bet to $8,392, illustrating how tech leverage ca...
As HOFT releases its Q1 2027 earnings, investors should focus on revenue trends, margins, and demand signals. This gu...
CarMax shares surged on Thursday after a rough session, driven by analyst upgrades and better-than-expected results. ...
NVIDIA’s edge in AI infrastructure goes beyond silicon speed. The real reason Nvidia holds its monopoly is a tightly ...
Tired of rewards that lock you into one brand? Credit cards with flexible rewards let you choose how to redeem points...
SK hynix prepares to begin trading on Nasdaq with ADRs priced at $149, in a move that broadens access to AI memory ex...